1. Home
  2. CRDL vs TBI Comparison

CRDL vs TBI Comparison

Compare CRDL & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Logo TrueBlue Inc.

TBI

TrueBlue Inc.

HOLD

Current Price

$6.25

Market Cap

165.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDL
TBI
Founded
2017
1985
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
154.1M
165.4M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
CRDL
TBI
Price
$1.23
$6.25
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$8.50
$6.00
AVG Volume (30 Days)
360.1K
380.9K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$6.25
Revenue Next Year
N/A
$3.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$3.18
52 Week High
$1.71
$7.78

Technical Indicators

Market Signals
Indicator
CRDL
TBI
Relative Strength Index (RSI) 38.48 69.21
Support Level $0.94 $5.44
Resistance Level $1.38 $6.22
Average True Range (ATR) 0.06 0.43
MACD -0.01 0.00
Stochastic Oscillator 5.26 83.19

Price Performance

Historical Comparison
CRDL
TBI

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.

Share on Social Networks: